Drugmakers’ alleged scare tactics may hold back competition

Source: Christopher Rowland, Washington Post (Paid Registration)

Health-care and government officials are growing concerned that the makers of the most advanced drug therapies are using scare tactics to ward off emerging generic versions of their products, a bid to protect profits that has enormous implications for the nation’s efforts to control health-care costs.

The campaign against those cheaper versions, known as biosimilars, could delay affordable access to a host of novel therapies, hurting patients and driving up health-care costs.

Read Full Article: Drugmakers’ alleged scare tactics may hold back competition

 

Tags/Keywords


 

Quick Menu

Support Consumer Action

Support Consumer

Join Our Email List

Optional Member Code
Facebook FTwitter T

Insurance Menu

Help Desk

Advocacy